SCHEMBL20135598

SCHEMBL20135598

Cc1ccc(C(=O)c2nnc(C3CCN(C(=O)c4ccc([C@@]5(C)NC(=O)NC5=O)cc4)CC3)o2)cc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TP53 P04637 3/20 0.49
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPK7 Q13164 1/20 0.39
LMNA P02545 4/20 0.38
ADCY1 Q08828 1/20 0.38
UBE2M P61081 1/20 0.38
DCUN1D1 Q96GG9 1/20 0.38
ALDH1A1 P00352 1/20 0.37
MMP2 P08253 1/20 0.37
MMP9 P14780 1/20 0.37
CRBN Q96SW2 2/20 0.37
THRB P10828 1/20 0.36
HSD11B1 P28845 1/20 0.36
MGLL Q99685 1/20 0.36
HTR2B P41595 1/20 0.36
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20135599 1.00 TP53 (0.49) TP53MEN1KMT2AMAPK7LMNA
SCHEMBL20135339 0.88 TP53 (0.54) TP53MEN1KMT2AHSD11B1MGLL
SCHEMBL20135338 0.88 TP53 (0.54) TP53MEN1KMT2AHSD11B1MGLL
SCHEMBL20134871 0.83 TP53 (0.53) TP53MEN1KMT2A
SCHEMBL29688759 0.83 TP53 (0.53) TP53MEN1KMT2A
SCHEMBL20134873 0.83 TP53 (0.53) TP53MEN1KMT2A
SCHEMBL20135705 0.80 LMNA (0.50) TP53MAPK7LMNAALDH1A1THRB
SCHEMBL20135701 0.80 LMNA (0.50) TP53MAPK7LMNAALDH1A1THRB
SCHEMBL20791693 0.79 UBE2M (0.40) MEN1KMT2AMAPK7UBE2MDCUN1D1
SCHEMBL20791691 0.79 UBE2M (0.40) MEN1KMT2AMAPK7UBE2MDCUN1D1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 TP53 4082/4885MEN1 3735/4885KMT2A 2568/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 TP53 3806/4885MEN1 2913/4885KMT2A 2539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.